← Human Trials & Peer-Reviewed Studies
Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS)
Plain-language guide to PMID 23589163 (2013): randomized controlled trial study of Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 23589163
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Schafer AL et al. (7 authors)
- DOI
- 10.1007/s00198-013-2349-y
- Registered trial
- NCT00683163
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84).
In postmenopausal women receiving combination parathyroid hormone (PTH) (1-84) therapy and ibandronate, the researchers evaluated bone microarchitecture and biomechanics using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Cortical and trabecular changes were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia.
Who Took Part
PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
HR-pQCT was performed before and after therapy.
What Was Measured
In postmenopausal women receiving combination parathyroid hormone (PTH) (1-84) therapy and ibandronate, the researchers evaluated bone microarchitecture and biomechanics using high-resolution peripheral quantitative computed tomography (HR-pQCT).
The researchers evaluated bone microarchitecture and biomechanics with HR-pQCT at the radius (a nonweight-bearing site) and tibia (weight bearing) in women receiving combination PTH(1-84) and ibandronate.
Topics PubMed links to this paper include Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Diphosphonates, Finite Element Analysis, Ibandronic Acid and Medication Adherence.
What This Means in Plain Language
The paper is a randomized study of Parathyroid Hormone (PTH 1-84).
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2013 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Parathyroid Hormone (PTH 1-84) compound page.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.